<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316715</url>
  </required_header>
  <id_info>
    <org_study_id>20190646</org_study_id>
    <secondary_id>R01MH118043</secondary_id>
    <nct_id>NCT04316715</nct_id>
  </id_info>
  <brief_title>Life-Steps Counseling to Enhance Adherence and Engagement in PrEP Care</brief_title>
  <official_title>Evaluation of Life-Steps to Enhance Adherence and Engagement in PrEP Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test how different types of interventions may affect how
      someone takes their pre-exposure prophylaxis (PrEP) medication.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TFV-DP concentrations</measure>
    <time_frame>3, 6, 9, 12, 15, and 18 months</time_frame>
    <description>Medication adherence as reported by Tenofovir diphosphate (TFV-DP) concentrations measured using dried blood spot (DBS) testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wilson Medication Adherence self-report</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Medication adherence as reported by the Wilson Medication Adherence self-report. The questionnaire has a total score ranging from 0-40, with a higher score indicating greater adherence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention in PrEP care</measure>
    <time_frame>3, 6, 9, 12, 15, and 18 months</time_frame>
    <description>The percentage of participant attendance at follow up visits over 18 month study participation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Adherence, Medication</condition>
  <arm_group>
    <arm_group_label>Life-Steps for PreP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive standard of care treatment plus daily text message reminders. A subset of participants who demonstrate continued adherence challenges will also receive 4-6 weekly sessions of the Lifesteps for PrEP intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this group will not receive an intervention outside the standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifesteps for PrEP</intervention_name>
    <description>Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.</description>
    <arm_group_label>Life-Steps for PreP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Daily text message reminders</intervention_name>
    <description>Participants get daily text messages on their cell phone reminding them to take their PrEP medication.</description>
    <arm_group_label>Life-Steps for PreP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18 years or older

          2. Male sex at birth

          3. Self-reports as a man who has sex with men

          4. PrEP na√Øve (started PrEP in the past month, or restarting after not taking for 6
             months or more)

          5. Medical providers at each site will determine that the participant is indicated for
             PrEP per CDC guidelines

          6. Screens in for currently having one or more of the following psychosocial syndemic
             problems: depression; heavy alcohol use; problematic substance use or polydrug use;
             history of trauma or abuse; and/or current interpersonal violence

          7. Owns a cell phone that has texting and internet / data capacity

        Exclusion Criteria:

          1. Unable to provide informed consent due to severe mental or physical illness, cognitive
             impairment, or substance intoxication at the time of interview

          2. Has lived in the greater Boston or Miami areas for less than three months (as a means
             to enhance participant retention)

          3. Discovery of active suicidal ideation or major mental illness (e.g. untreated
             psychosis or mania) at the time of enrollment (these patients will be referred
             immediately for treatment, but may join the study when this is resolved)

          4. Laboratory or clinical findings that would preclude PrEP initiation (e.g. decreased
             creatinine clearance)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Safren, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Puccinelli, Ph.D.</last_name>
    <phone>3052433508</phone>
    <email>mpuccinelli@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Puccinelli, Ph.D.</last_name>
      <phone>305-243-3508</phone>
      <email>mpuccinelli@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Steven A Safren, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fenway Health</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jairan Sadeghi, BSN</last_name>
      <phone>857-313-6978</phone>
      <email>jsadeghi@fenwayhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Mayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Steven Safren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Life-Steps</keyword>
  <keyword>HIV Prevention</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

